Autolus Therapeutics

The US FDA has granted Autolus’ cell therapy Obecabtagene Autoleucel (Obe-cel) RMAT designation for the treatment of systemic lupus erythematosus and lupus nephritis to accelerate development and review. The designation is based on data from the phase 1b CARLYSLE study. The approval‑enabling phase 2 study LUMINA is currently recruiting in five countries; Autolus expects study data in 2028 and has submitted a data update for the ACR annual meeting in Q4 2026. » More on de.investing.com

Autolus Therapeutics granted inducement awards under its 2025 Inducement Plan comprising options to purchase 25,420 American Depositary Shares and 87,530 restricted stock units to 13 new hires. Awards have a grant date of June 24, 2026; options carry a $1.66 exercise price, a ten-year term and vest over four years, while RSUs vest in four equal annual installments. The grants were made in accordance with Nasdaq Listing Rule 5635(c)(4). » More on finance.yahoo.com

Autolus Therapeutics has published its UK annual report for the fiscal year ended 31 December 2025 and has convened the annual general meeting for 29 June 2026. The report, the notice of the AGM and a proxy form were sent to ordinary shareholders on 5 June; Citibank, as depositary bank, began sending notifications to ADS holders around 8 June. ADS holders who were registered as shareholders on 27 May can instruct the depositary bank to exercise their voting rights, although exercising those rights may be delayed or not occur in time due to practical and legal constraints. » More on de.investing.com